COMMUNIQUÉS West-GlobeNewswire

Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024
21/03/2024
Live Conference Call and Webcast at 8:30 a.m. ET PRINCETON, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report fourth quarter [...]
Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024
21/03/2024
MANNHEIM, Germany, March 21, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight [...]
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
21/03/2024
Launch preparations underway in anticipation of possible U.S. approval of mavorixafor for WHIM syndrome; U.S. PDUFA target action date set for April 30, 2024 Additional Phase 2 clinical data and initiation of global [...]
Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder
21/03/2024
BNC210 demonstrated a statistically significant improvement in post-traumatic stress disorder (PTSD) symptom severity with a clinically meaningful effect size suggesting a potential advantage over approved medications. [...]
Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update
21/03/2024
~ Achieved PEDMARK ® Full-Year 2023 Net Product Sales of $21.3 Million, Including $9.7 Million in Net Product Sales in the Fourth Quarter of 2023 ~ ~ Entered Into Exclusive Licensing Agreement to Commercialize PEDMARQSI [...]
Angelini Ventures invests into extended €75.8 million ($82 million) Series C financing round for Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized cancer vaccines
21/03/2024
Angelini Ventures joins syndicate of top-tier international healthcare investors in Nouscom’s Series C financing round Financing will enable Nouscom to continue advancing the clinical development of its portfolio of [...]
CMR Surgical announces over 20,000 surgical cases completed using Versius
21/03/2024
Over 20,000 surgical cases completed using Versius The versatile surgical robot Versius has now been used to perform over 20,000 surgical cases across seven specialties with data collected in the clinical registry and [...]
2024 outlook and pro forma financials
21/03/2024
Novonesis provides outlook for 2024 with expected 5-7% organic sales growth and ~35% adj. EBITDA margin. Pro forma financials disclosed. Ester Baiget, CEO of Novonesis , said: “Today we provide key pro forma numbers as [...]
Ultimovacs ASA: Annual Report 2023
21/03/2024
Oslo, 21 March 2024: Ultimovacs ASA (“Ultimovacs”, ticker ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announces that the Board of Directors of Ultimovacs ASA has approved the [...]
Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C.
21/03/2024
Saint-Herblain (France), March 21, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced it will present on its single-shot chikungunya vaccine, IXCHIQ ® , moderate a [...]
Valneva fera une présentation sur son vaccin contre le chikungunya, IXCHIQ®, et participera à plusieurs événements lors du 24ème World Vaccine Congress à Washington, D.C.
21/03/2024
Saint-Herblain (France), le 21 mars 2024 – Valneva SE (Nasdaq : VALN; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui qu’elle fera une présentation sur son vaccin à injection unique [...]
IBA Reports Full Year 2023 Results
21/03/2024
GROUP REVENUES UP 18.7% WITH OTHER ACCELERATORS UP 51.1% REBIT POSITIVE FOR FY23 WITH OTHER ACCELERATORS REBIT ALMOST QUADRUPLING MEDIUM TERM GUIDANCE REITERATED Louvain-la-Neuve, Belgium, 21 March 2024 - IBA (Ion Beam [...]
IBA publie ses résultats annuels pour 2023
21/03/2024
REVENUS DU GROUPE EN HAUSSE DE 18,7% AUTRES ACCÉLÉRATEURS EN HAUSSE DE 51,1% REBIT POSITIF POUR L’EXERCICE 2023 REBIT AUTRES ACCÉLERATEURS PRESQUE QUADRUPLÉ PRÉVISIONS À MOYEN-TERME RÉITÉRÉES Louvain-La-Neuve, Belgique [...]
NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine
21/03/2024
NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine ClC-1 is a chloride ion channel specifically expressed in skeletal muscle cells that normally dampens muscle fiber [...]
SEQUANA MEDICAL SUCCESSFULLY RAISES EUR 11.5 MILLION IN AN EQUITY PLACEMENT
21/03/2024
THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW [...]
ONWARD® Medical Successfully Raises €20 Million in a Capital Increase by Way of an Accelerated Bookbuild Offering and by Way of a Public Offering in France
21/03/2024
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE [...]
ONWARD® Medical Lève avec Succès 20 millions d'euros dans le cadre d'une Augmentation de Capital par le biais d'une Procédure de Construction Accélérée d'un Livre d'Ordres et d'une Offre au Public en France
21/03/2024
NE PAS DISTRIBUER OU DIFFUSER, DIRECTEMENT OU INDIRECTEMENT, AUX ÉTATS-UNIS, AU CANADA, EN AUSTRALIE OU AU JAPON OU DANS TOUTE AUTRE JURIDICTION DANS LAQUELLE LA DISTRIBUTION OU LA DIFFUSION SERAIT ILLÉGALE. D'AUTRES [...]
Sosei Heptares Doses First Subject in Phase 1 Trial with HTL0033744, an EP4 Agonist for Inflammatory Bowel Disease
21/03/2024
HTL0033744 has been designed by Sosei Heptares to promote mucosal healing and resolve inflammation in people with IBD Tokyo, Japan and Cambridge, UK, 21 March 2024 – Sosei Group Corporation (“Sosei Heptares” or “the [...]
Sosei Heptares Regains Full Ownership from GSK of HTL0027477, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease
21/03/2024
GPR35 is a novel target with an established genetic association to IBD UK regulatory approval received to commence first-in-human studies Return of rights follows change in immunology research strategy by GSK Tokyo, [...]

Pages